1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial.
Saved in:
| Title: | 1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial. |
|---|---|
| Authors: | Capdevila Castillon, J.1 (AUTHOR), Plana, M.2 (AUTHOR), Castelo, B.3 (AUTHOR), Iglesias, L.4 (AUTHOR), Hernando, J.1 (AUTHOR), Yaya Tur, R.5 (AUTHOR), Baste, N.6 (AUTHOR), Carmona-Bayonas, A.7 (AUTHOR), Ruiz, S.8 (AUTHOR), Trigo, J.8 (AUTHOR), Lorenzo-Lorenzo, I.9 (AUTHOR), Grande, E.10 (AUTHOR), Lorente, D.11 (AUTHOR), Ugidos, L.12 (AUTHOR), Marquina, G.13 (AUTHOR), García-Alvarez, A.1 (AUTHOR), Taberna, M.2 (AUTHOR), Villamayor, J.14 (AUTHOR), Molina-Cerrillo, J.15 (AUTHOR), Alonso-Gordoa, T.15 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1294-S1295. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.1725 |
